Can a nasal spray calm social anxiety? trial ends early

NCT ID NCT05011396

Terminated Symptom relief Sponsor: VistaGen Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a nasal spray called PH94B to see if it could quickly reduce anxiety in adults with social anxiety disorder during a public speaking task. About 228 participants were expected to take the spray or a placebo before speaking. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

social phobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOCIAL ANXIETY DISORDER

Contacts and locations

Locations

VistaGen Clinical Center

Allentown, Pennsylvania, 18104, United States
VistaGen Clinical Site

Phoenix, Arizona, 85012, United States
VistaGen Clinical Site

Garden Grove, California, 92845, United States
VistaGen Clinical Site

Oceanside, California, 92056, United States
VistaGen Clinical Site

Temecula, California, 92591, United States
VistaGen Clinical Site

Alpharetta, Georgia, 30022, United States
VistaGen Clinical Site

Prairie Village, Kansas, 66208, United States
VistaGen Clinical Site

Boston, Massachusetts, 02131, United States
VistaGen Clinical Site

Flowood, Mississippi, 39232, United States
VistaGen Clinical Site

Berlin, New Jersey, 08009, United States
VistaGen Clinical Site

Brooklyn, New York, 11235, United States
VistaGen Clinical Site

New York, New York, 10032, United States
VistaGen Clinical Site

Rochester, New York, 14618, United States
VistaGen Clinical Site

Memphis, Tennessee, 38119, United States
VistaGen Clinical Site

Austin, Texas, 78737, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.